Clinical trial readout dates for Celldex Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is June 2028.
| Phase 3 Barzolvolimab Chronic Inducible Urticaria; Cold Urticaria · NCT07266402 | June 2028 Recruiting |
| Phase 3 barzolvolimab Chronic Spontaneous Urticaria · NCT07256392 | September 2028 Enrolling |
Celldex Therapeutics Inc. reported $650M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-05). Its net loss for that quarter was $76M; at that rate the cash would last about 9 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-05 |